Lantus [insulin glargine] vs sulfonylurea as add-on therapy in type 2 diabetic patients failing metformin monotherapy: Comparison of effects on beta cell function and metabolic profile.

Trial Profile

Lantus [insulin glargine] vs sulfonylurea as add-on therapy in type 2 diabetic patients failing metformin monotherapy: Comparison of effects on beta cell function and metabolic profile.

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Dec 2013

At a glance

  • Drugs Glimepiride; Insulin glargine
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms BETA
  • Sponsors Sanofi
  • Most Recent Events

    • 10 Dec 2013 Treatment table added.
    • 16 Jul 2012 Additional lead trial investigator (Ji Young Ahn) identified as reported by ClinicalTrials.gov.
    • 16 Jul 2012 Actual initiation date changed from Oct 2007 to Sep 2007 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top